1. AN ONGOING PHASE 1/1B TRIAL INVESTIGATING NOVEL TREATMENT REGIMENS WITH MOSUNETUZUMAB IN RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA. (12th June 2019) Authors: Kim, W.S.; Assouline, S.; Bartlett, N.L.; Bosch, F.; Budde, L.E.; Cheah, C.; Gregory, G.P.; Hong, J.; Ku, M.; Marlton, P.; Matasar, M.; Nastoupil, L.; Panizo, C.; Sehn, L.H.; Tzachanis, D.; Chu, W.; Hernandez, M.G.; Kwan, A.; Li, C.C.; Sison, I. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 567 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. HIGH OVERALL RESPONSE RATE WITH THE BTK INHIBITOR BGB‐3111 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: AN UPDATE ON SAFETY AND ACTIVITY. (June 2017) Authors: Seymour, J.F.; Opat, S.; Cull, G.; Trotman, J.; Gottlieb, D.; Simpson, D.; Marlton, P.; Anderson, M.; Ku, M.; Ritchie, D.S.; Ratnasingam, S.; Augustson, B.; Kim, W.; Wang, L.; Xue, L.; Hilger, J.; Huang, J.; Hedrick, E.; Roberts, A.W.; Tam, C.S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY. (23rd June 2022) Authors: Matasar, M.; Bartlett, N. L.; Sehn, L. H.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; Ku, M.; Nastoupil, L. J.; Wei, M. C.; Yin, S.; To, I.; Turner, D.; Huang, H.; Min, J.; Penuel, E.; Budde, L. E. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1016 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗